Abbott posts profit beat CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.
UPDATE 1-Teva ready to divest operations to win regulatory nod for Mylan buy April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.
UPDATE 1-Abbott profit beats expectations, sales of branded generics jump April 22- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.